TGR BioSciences Collaborates with PerkinElmer in Launch of New AlphaLISA® SureFire® Ultra Assays

PerkinElmer’s Advanced Offering Reduces Assay Time By Up to 50 Percent and Enhances Detection Process for Life Science Researchers

WHAT:

TGR BioSciences, a leading innovator of immunoassay technologies and products, today announced a collaboration with PerkinElmer, Inc. in PerkinElmer’s launch of its AlphaLISA® SureFire® Ultra™ assays. These solutions are designed to reduce assay time by up to 50 percent and to improve the protein phosphorylation detection process. This is a critical process for helping life science professionals obtain more accurate results in biotherapeutic drug discovery research.

With high sensitivity and wide dynamic range to detect protein phosphorylation, even at low levels, AlphaLISA SureFire Ultra assays are quick and easy to run with a minimal amount of sample, significantly reducing time and expense. Researchers can use the assays to analyze cell lysates or tissue lysates whether they are treated with therapeutic antibodies or small molecules.

“TGR is focused on delivering the best technologies for the rapid analysis of complex samples. Incorporation of TGR’s CaptSure™ technology into the proven AlphaLISA® system provides an advanced level of sample analysis. It can be used for virtually all types of samples, including therapeutic antibodies, tissue lysates and small molecules, in addition to standard samples, such as cell lysates,” said Anne Hinton, CEO of TGR BioSciences.

The assays also leverage PerkinElmer’s AlphaLISA technology which has better spectral characteristics related to hemoglobin interference, which can otherwise hinder the accuracy of measurements. AlphaLISA SureFire Ultra generates results in less than 21⁄2 hours with only one or two incubation steps and no washing. Researchers can analyze different endogenous or transfected targets in parallel – all on the same plate.

As a mix-and-read technology, with no wash steps, assays can be carried out with full automation if required, allowing very large sample numbers to be assessed. Equally, the assay simplicity means standard laboratory sample numbers can be rapidly assayed manually with ease.

Please visit www.tgrbio.com or www.perkinelmer.com/surefire for more information and to view the full product listing.

HOW THEY WORK:

The AlphaLISA SureFire Ultra assays use TGR BioSciences’ CaptSureTM technology to eliminate antibody interference in the therapeutic antibody screening process. AlphaLISA SureFire Ultra sensitivity and dynamic range also make it ideal for other types of screening, such as small molecule modulation, detection of low and basal levels of phosphorylation and detection of phosphorylation in tissue lysates.

The assays also leverage PerkinElmer’s AlphaLISA technology which has better spectral characteristics related to hemoglobin interference, which can otherwise hinder the accuracy of measurements. AlphaLISA SureFire Ultra generates results in less than 21⁄2 hours with only one or two incubation steps and no washing. Researchers can analyze different endogenous or transfected targets in parallel – all on the same plate.

As a mix-and-read technology, with no wash steps, assays can be carried out with full automation if required, allowing very large sample numbers to be assessed. Equally, the assay simplicity means standard laboratory sample numbers can be rapidly assayed manually with ease.

Please visit www.tgrbio.com or www.perkinelmer.com/surefire for more information and to view the full product listing.


Media enquiries

Anne Hinton, Managing Director
TGR BioSciences
P: +61 (0)8 8354 6174
E: ahinton@tgrbio.com